

	Day 1 FDV EC_{50} ± SD (n)
1a Q80K	8 nM (1)
1a non-Q80K	12 nM (1)
placebo*	9 ± 3 (2)

	Day 1 FDV EC_{50} ± SD (n)
1a Q80K	42 nM (1)
1a non-Q80K	8 ± 4 nM (2)
placebo*	13 ± 5 (2)

	Day 1 FDV EC_{50} ± SD (n)
1a Q80K	20 nM (1)
1a non-Q80K	5 ± 2 nM (2)
placebo*	8 ± 5 (2)

	Day 1 FDV EC_{50} ± SD (n)
1a Q80K	15 nM (1)
1a non-Q80K	14 ± 7 nM (2)

	Day 1 FDV EC_{50} ± SD (n)
1a Q80K	37 nM (1)
1a non-Q80K	8 ± 3 nM (3)

	Day 1 FDV EC_{50} ± SD (n)
1a Q80K	28 ± 9 nM (2)
1a non-Q80K	9 ± 4 nM (6)

Supplementary FIG 1. Initial viral load decline (days 1 to 6) in GT-1a-infected patients with and without baseline NS3 Q80K virus. Individual patient baseline samples were phenotyped in n≥3 independent experiments; and the tables below the graphs show the weighted mean EC50 ± standard deviation (SD) of faldaprevir (FDV) for GT-1a baseline samples within the dose group calculated. n = number of patients with VL and EC50 data shown. *Placebo includes GT1b and/or GT1a patients.



	Day 1 FDV EC_{50} ± SD (n)	
■	1b V170T	63 nM (1)
○	1b non-V170T	7 ± 6 nM (2)
▲	placebo*	9 ± 2 (2)

Supplementary FIG 2. Initial viral load decline (days 1 to 6) in GT-1b-infected patients with and without baseline NS3 V170T virus. Individual patient baseline samples were phenotyped in n≥3 independent experiments; and the tables below the graphs show the weighted mean EC50 ± standard deviation (SD) of faldaprevir (FDV) for GT-1b baseline samples within the TN, 20 mg, QD dose group. n = number of patients with VL and EC50 data shown.
*Placebo includes GT1b and/or GT1a patients.



Supplementary FIG 3. Longitudinal clonal sequence analysis. Viral load profiles of virologic breakthrough and % of clones encoding NS3 R155 and/or D168 substitutions over time for representative patients:
(A) TN GT-1a-infected patient from the 20 mg dose group and
(B) TE GT-1b-infected patient from the 48 mg dose group.
*R155X+D168X mix includes R155Q+D168V, R155S+D168N, or R155K+D168G